^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AXL overexpression

    i
    Other names: AXL Receptor Tyrosine Kinase, Tyrosine Protein Kinase Receptor UFO, AXL Oncogene, AXL Transforming Sequence Gene, Tyro7
    Entrez ID:
    558
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (ADVL1622) (NCT02867592)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/18/2017
    Primary completion :
    06/30/2021
    Completion :
    09/21/2024
    MET • RET • AXL
    |
    MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity (NCT01639508)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/26/2023
    Initiation :
    07/01/2012
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    RET • ROS1 • KIF5B • AXL • NTRK
    |
    RET fusion • MET overexpression • KIF5B-RET fusion • ROS1 fusion • AXL overexpression • NTRK fusion
    |
    Cabometyx (cabozantinib tablet)